SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate a major catalyst from the final survival event in the Phase 3 REGAL trial, with the stock seeing intense volatility driven by a massive short squeeze. Community members are actively debating the timing of a potential buyout and the drug's long-term curative potential, while the tightening liquidity and extreme borrow costs continue to trap short sellers in a high-pressure environment.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is experiencing a significant defensive rotation as market capital pivots from high-beta technology and AI toward established healthcare stalwarts with visible cash flows. The stock's positive performance is further bolstered by institutional confidence in its oncology pipeline, a fresh dividend hike, and active speculation regarding the potential sale of its multi-billion dollar orthopedics division.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing significant attention from the investment community due to its strategic positioning in ruggedized edge computing, which is essential for the expanding physical AI, robotics, and defense infrastructure sectors. Discussions are heavily focused on the company's strong contract pipeline, recent earnings performance, and positive momentum from upcoming index inclusion, with many participants viewing it as an under-the-radar player poised to capitalize on the shift of AI workloads beyond traditional data centers.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as investors debate whether the recent volatility represents a healthy consolidation phase or a deeper structural correction within the AI hardware supply chain. The community is focused on the critical role of Indium Phosphide (InP) substrates as a production bottleneck for high-speed AI optical networking, with ongoing discussions centered on whether recent price fluctuations offer an accumulation window or signal potential downside risks.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as a top healthcare leader due to groundbreaking Phase 3 clinical data for its obesity and diabetes pipeline, which has ignited investor excitement regarding its long-term growth prospects. The community is actively discussing this news, alongside broader market rotation into defensive, high-quality pharmaceutical names as participants look to balance their portfolios.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

The community is actively discussing the potential acquisition of Churchill Capital Corp XI following the merger announcement with Agility Robotics, with many investors debating the long-term viability of the robotics sector and comparing the situation to previous SPAC experiences. Bullish sentiment is driven by the company's backing from major tech players, while others remain skeptical, warning of potential volatility and cautioning against post-merger price fluctuations.

Ambarella, Inc. engages in the development of low-power system-on-a-chip (SoC), semiconductors, and software for edge artificial intelligence (AI) applications and intelligent automation. The firm's products include video security, advanced driver assistance (ADAS), electronic mirror, drive recorder, driver or cabin monitoring, autonomous driving, and other robotics applications. It operates through the following geographical segments: Taiwan, Asia Pacific, Europe, North America, and United States. The company was founded by Feng Ming Wang and Leslie D. Kohn on January 15, 2004 and is headquartered in Santa Clara, CA.

Ambarella Inc

Ambarella is seeing significant investor attention following reports that the company is working with bankers to explore strategic options, including a potential sale. The community is actively discussing the implications of this M&A speculation, with many highlighting its long-term potential as a key enabler in the edge AI and robotics hardware supply chain.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF is currently navigating institutional volatility and defensive hedging, with the community actively debating whether it serves as a reliable anchor during rotation into tech-heavy sectors or if the broader market is flashing signs of an over-extended bubble. Investors are primarily focused on the ETF's utility as a long-term 'set it and forget it' compounding tool while weighing the impact of elevated CapEx and macroeconomic uncertainty on future growth.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending as investors weigh its aggressive share buyback program and expanding autonomous vehicle partnerships against heavy short interest and persistent concerns regarding profitability. Community discussions remain polarized, with many focusng on its potential as an undervalued asset and long-term buyout target, while others express ongoing frustration with the stock's stagnant price action and competition from Uber.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is seeing significant investor attention following a broader sector rotation into defensive, high-cash-flow healthcare stocks as capital shifts away from higher-beta technology shares. Community discussion is heavily focused on the company's recent strategic M&A activity to strengthen its drug development pipeline and its ability to maintain strong performance despite broader market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$26.74
Prev Close	N/A
Open	$26.74
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

TUMITumi Holdings, Inc.

Latest TUMI News